Product Description
A novel, small peptide antagonist of the growth hormone receptor (GHR), being developed as a combination therapy to SSAs to further suppress and normalize IGF1 levels. ALXN2420 bound to the human GHR and inhibited its activation by GH in vitro. In vivo, ALXN2420 administration efficiently reduced IGF1 levels, which was associated with reduced growth in juvenile rats. Importantly, when combined with a SSA, ALXN2420 demonstrated an additive effect on IGF1 reduction. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/40067863/)
Mechanisms of Action: GHR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Brazil, China, Denmark, Hungary, Italy, Lithuania, Netherlands, Poland, Romania, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acromegaly
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07037420 |
ASTERIA | P2 |
Recruiting |
Acromegaly |
2027-01-08 |
50% |
2026-02-04 |
Primary Endpoints |
2025-521243-20-00 |
ALXN2420-Acro-201 | P2 |
Not yet recruiting |
Acromegaly |
2027-12-31 |
Recent News Events
Date |
Type |
Title |
|---|